Prospects and Challenges in the Development of a Norovirus Vaccine

Clinical Therapeutics

Volumn 39, Issue 8, 2017, Pages 1537-1549

  Cortes Penfield, Nicolas W ^a   Ramani, Sasirekha ^a   Estes, Mary K ^a   Atmar, Robert L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

acute gastroenteritis; calicivirus; norovirus; prevention; vaccine

Indexed keywords

ADENOVIRUS VECTOR; ALUMINUM HYDROXIDE; BLOOD GROUP ANTIGEN; HEMAGGLUTINATION INHIBITING ANTIBODY; HISTO BLOOD GROUP ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; NANOTUBE; NEUTRALIZING ANTIBODY; NOROVIRUS VACCINE; PHOSPHORYL LIPID A; PLACEBO; PROTEIN VP1; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE; VIRUS VACCINE;

ACUTE GASTROENTERITIS; ANTIBODY RESPONSE; CORRELATION ANALYSIS; DRUG EFFECT; DRUG EFFICACY; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE; IMMUNITY; MEDLINE; NONHUMAN; NOROVIRUS INFECTION; PRECLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; UNITED STATES; VACCINATION; VACCINE IMMUNOGENICITY; VIROLOGY; VIRUS GENOME; VIRUS STRAIN; ANIMAL; CALICIVIRUS INFECTION; IMMUNOLOGY; NOROVIRUS;

ANIMALS; CALICIVIRIDAE INFECTIONS; HUMANS; NOROVIRUS; VIRAL VACCINES;

EID: 85025831396     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2017.07.002     Document Type: Review

References (71)

1. Hall, A.J., Lopman, B.A., Payne, D.C., et al. Norovirus disease in the United States. Emerging Infect Dis 19 (2013), 1198–1205.
2. Vega, E., Barclay, L., Gregoricus, N., et al. Genotypic and epidemiologic trends of norovirus outbreaks in the United States, 2009 to 2013. J Clin Microbiol 52 (2014), 147–155.
3. Payne, D.C., Vinjé, J., Szilagyi, P.G., et al. Norovirus and medically attended gastroenteritis in U.S. children. N Engl J Med 368 (2013), 1121–1130.
4. Koo, H.L., Neill, F.H., Estes, M.K., et al. Noroviruses: The Most Common Pediatric Viral Enteric Pathogen at a Large University Hospital After Introduction of Rotavirus Vaccination. J Pediatric Infect Dis Soc 2 (2013), 57–60.
5. Bartsch, S.M., Lopman, B.A., Ozawa, S., et al. Global Economic Burden of Norovirus Gastroenteritis. PLoS ONE, 11, 2016, e0151219.
6. Ahmed, S.M., Hall, A.J., Robinson, A.E., et al. Global prevalence of norovirus in cases of gastroenteritis: a systematic review and meta-analysis. Lancet Infect Dis 14 (2014), 725–730.
7. Bartsch, S.M., Lopman, B.A., Hall, A.J., et al. The potential economic value of a human norovirus vaccine for the United States. Vaccine 30 (2012), 7097–7104.
8. Tallant, A., Porter, C.K., Putnam, S.D., et al. Relative cost-effectiveness of a norovirus vaccine in the deployed military setting compared to a vaccine against Campylobacter sp., ETEC, and Shigella sp. Vaccine 32 (2014), 5156–5162.
9. Kroneman, A., Vega, E., Vennema, H., et al. Proposal for a unified norovirus nomenclature and genotyping. Arch Virol 158 (2013), 2059–2068.
10. Malm, M., Tamminen, K., Lappalainen, S., et al. Genotype considerations for virus-like particle-based bivalent norovirus vaccine composition. Clin Vaccine Immunol 22 (2015), 656–663.
11. Malm, M., Uusi-kerttula, H., Vesikari, T., Blazevic, V., High serum levels of norovirus genotype-specific blocking antibodies correlate with protection from infection in children. J Infect Dis 210 (2014), 1755–1762.
12. Lindesmith, L.C., Beltramello, M., Donaldson, E.F., et al. Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog, 8, 2012, e1002705.
13. Sharma, S., Carlsson, B., Czakó, R., et al. Human Sera Collected between 1979 and 2010 Possess Blocking-Antibody Titers to Pandemic GII.4 Noroviruses Isolated over Three Decades. J Virol, 91, 2017: e00567-17.
14. Czakó, R., Atmar, R.L., Opekun, A.R., et al. Experimental human infection with Norwalk virus elicits a surrogate neutralizing antibody response with cross-genogroup activity. Clin Vaccine Immunol 22 (2015), 221–228.
15. Clarke, I.N., Lambden, P.R., The molecular biology of human caliciviruses. Novartis Found Symp 238 (2001), 180–191.
16. Chen, R., Neill, J.D., Noel, J.S., et al. Inter- and intragenus structural variations in caliciviruses and their functional implications. J Virol 78 (2004), 6469–6479.
17. Green, K.Y., Lew, J.F., Jiang, X., et al. Comparison of the reactivities of baculovirus-expressed recombinant Norwalk virus capsid antigen with those of the native Norwalk virus antigen in serologic assays and some epidemiologic observations. J Clin Microbiol 31 (1993), 2185–2191.
18. Jiang, X., Wang, M., Graham, D.Y., Estes, M.K., Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J Virol 66 (1992), 6527–6532.
19. Ball, J.M., Hardy, M.E., Atmar, R.L., et al. Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice. J Virol 72 (1998), 1345–1353.
20. Guerrero, R.A., Ball, J.M., Krater, S.S., et al. Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses. J Virol 75 (2001), 9713–9722.
21. Tan, M., Jiang, X., The p domain of norovirus capsid protein forms a subviral particle that binds to histo-blood group antigen receptors. J Virol 79 (2005), 14017–14030.
22. Ramani, S., Estes, M.K., Atmar, R.L., Correlates of Protection against Norovirus Infection and Disease-Where Are We Now, Where Do We Go?. PLoS Pathog, 12, 2016, e1005334.
23. Parrino, T.A., Schreiber, D.S., Trier, J.S., et al. Clinical immunity in acute gastroenteritis caused by Norwalk agent. N Engl J Med 297 (1977), 86–89.
24. Simmons, K., Gambhir, M., Leon, J., Lopman, B., Duration of immunity to norovirus gastroenteritis. Emerging Infect Dis 19 (2013), 1260–1267.
25. Ettayebi, K., Crawford, S.E., Murakami, K., et al. Replication of human noroviruses in stem cell-derived human enteroids. Science 353 (2016), 1387–1393.
26. Karst, S.M., Identification of a novel cellular target and a co-factor for norovirus infection - B cells & commensal bacteria. Gut Microbes 6 (2015), 266–271.
27. Jones, M.K., Grau, K.R., Costantini, V., et al. Human norovirus culture in B cells. Nat Protoc 10 (2015), 1939–1947.
28. Plotkin, S.A., Gilbert, P.B., Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis 54 (2012), 1615–1617.
29. Johnson, P.C., Mathewson, J.J., Dupont, H.L., Greenberg, H.B., Multiple-challenge study of host susceptibility to Norwalk gastroenteritis in US adults. J Infect Dis 161 (1990), 18–21.
30. Ryder, R.W., Singh, N., Reeves, W.C., et al. Evidence of immunity induced by naturally acquired rotavirus and Norwalk virus infection on two remote Panamanian islands. J Infect Dis 151 (1985), 99–105.
31. Kim, S.H., Chen, S., Jiang, X., et al. Newcastle disease virus vector producing human norovirus-like particles induces serum, cellular, and mucosal immune responses in mice. J Virol 88 (2014), 9718–9727.
32. Reeck, A., Kavanagh, O., Estes, M.K., et al. Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis 202 (2010), 1212–1218.
33. Czakó, R., Atmar, R.L., Opekun, A.R., et al. Serum hemagglutination inhibition activity correlates with protection from gastroenteritis in persons infected with Norwalk virus. Clin Vaccine Immunol 19 (2012), 284–287.
34. Atmar, R.L., Bernstein, D.I., Harro, C.D., et al. Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med 365 (2011), 2178–2187.
35. Ohmit, S.E., Petrie, J.G., Cross, R.T., et al. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis 204 (2011), 1879–1885.
36. Ramani, S., Neill, F.H., Opekun, A.R., et al. Mucosal and Cellular Immune Responses to Norwalk Virus. J Infect Dis 212 (2015), 397–405.
37. Wyatt, R.G., Dolin, R., Blacklow, N.R., et al. Comparison of three agents of acute infectious nonbacterial gastroenteritis by cross-challenge in volunteers. J Infect Dis 129 (1974), 709–714.
38. Lindesmith, L.C., Ferris, M.T., Mullan, C.W., et al. Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial. PLoS Med, 12, 2015, e1001807.
39. O'Ryan, M.L., Lucero, Y., Prado, V., et al. Symptomatic and asymptomatic rotavirus and norovirus infections during infancy in a Chilean birth cohort. Pediatr Infect Dis J 28 (2009), 879–884.
40. Blazevic, V., Malm, M., Salminen, M., et al. Multiple consecutive norovirus infections in the first 2 years of life. Eur J Pediatr 174 (2015), 1679–1683.
41. Menon, V.K., George, S., Sarkar, R., et al. Norovirus Gastroenteritis in a Birth Cohort in Southern India. PLoS ONE, 11, 2016, e0157007.
42. Blazevic, V., Lappalainen, S., Nurminen, K., et al. Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis. Vaccine 29 (2011), 8126–8133.
43. Guo, L., Wang, J., Zhou, H., et al. Intranasal administration of a recombinant adenovirus expressing the norovirus capsid protein stimulates specific humoral, mucosal, and cellular immune responses in mice. Vaccine 26 (2008), 460–468.
44. Tan, M., Fang, P., Chachiyo, T., et al. Noroviral P particle: structure, function and applications in virus-host interaction. Virology 382 (2008), 115–123.
45. Ball, J.M., Graham, D.Y., Opekun, A.R., et al. Recombinant Norwalk virus-like particles given orally to volunteers: phase I study. Gastroenterology 117 (1999), 40–48.
46. El-Kamary, S.S., Pasetti, M.F., Mendelman, P.M., et al. Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J Infect Dis 202 (2010), 1649–1658.
47. Ramirez, K., Wahid, R., Richardson, C., et al. Intranasal vaccination with an adjuvanted Norwalk virus-like particle vaccine elicits antigen-specific B memory responses in human adult volunteers. Clin Immunol 144 (2012), 98–108.
48. Parra, G.I., Bok, K., Taylor, R., et al. Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations. Vaccine 30 (2012), 3580–3586.
49. Treanor, J.J., Atmar, R.L., Frey, S.E., et al. A novel intramuscular bivalent norovirus virus-like particle vaccine candidate-reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults. J Infect Dis 210 (2014), 1763–1771.
50. Sundararajan, A., Sangster, M.Y., Frey, S., et al. Robust mucosal-homing antibody-secreting B cell responses induced by intramuscular administration of adjuvanted bivalent human norovirus-like particle vaccine. Vaccine 33 (2015), 568–576.
51. Ramani, S., Neill, F.H., Ferreira, J., et al. B-Cell Responses to Intramuscular Administration of a Bivalent Virus-like Particle Human Norovirus Vaccine. Clin Vaccine Immunol, 24, 2017: e00571-16.
52. Bernstein, D.I., Atmar, R.L., Lyon, G.M., et al. Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults. J Infect Dis 211 (2015), 870–878.
53. Atmar, R.L., Baehner, F., Cramer, J.P., et al. Rapid Responses to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: A Randomized Controlled Trial. J Infect Dis 214 (2016), 845–853.
54. Guo, L., Zhou, H., Wang, M., et al. A recombinant adenovirus prime-virus-like particle boost regimen elicits effective and specific immunities against norovirus in mice. Vaccine 27 (2009), 5233–5238.
55. Liebowitz, D., Lindbloom, J.D., Brandl, J.R., et al. High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial. Lancet Infect Dis 15 (2015), 1041–1048.
56. Vaxart Announces Positive Phase 1 Study of Oral Norovirus Vaccine, 2017 http://www.vaxart.com/NRfiles/VaxartAnnouncesNorovirusPhaseIResults021417.pdf Accessed April 17, 2017.
57. Tamminen, K., Lappalainen, S., Huhti, L., et al. Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice. PLoS ONE, 8, 2013, e70409.
58. Malm, M., Tamminen, K., Lappalainen, S., et al. Rotavirus Recombinant VP6 Nanotubes Act as an Immunomodulator and Delivery Vehicle for Norovirus Virus-Like Particles. J Immunol Res, 2016, 2016, 9171632.
59. Tan, M., Huang, P., Xia, M., et al. Norovirus P particle, a novel platform for vaccine development and antibody production. J Virol 85 (2011), 753–764.
60. Xia, M., Tan, M., Wei, C., et al. A candidate dual vaccine against influenza and noroviruses. Vaccine 29 (2011), 7670–7677.
61. Elaish, M., Ngunjiri, J.M., Ali, A., et al. Supplementation of inactivated influenza vaccine with norovirus P particle-M2e chimeric vaccine enhances protection against heterologous virus challenge in chickens. PLoS ONE, 12, 2017, e0171174.
62. Wang, L., Cao, D., Wei, C., et al. A dual vaccine candidate against norovirus and hepatitis E virus. Vaccine 32 (2014), 445–452.
63. Kocher, J., Bui, T., Giri-rachman, E., et al. Intranasal P particle vaccine provided partial cross-variant protection against human GII.4 norovirus diarrhea in gnotobiotic pigs. J Virol 88 (2014), 9728–9743.
64. Harrington, P.R., Yount, B., Johnston, R.E., et al. Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles. J Virol 76 (2002), 730–742.
65. Mathew, L.G., Herbst-kralovetz, M.M., Mason, H.S., Norovirus Narita 104 virus-like particles expressed in Nicotiana benthamiana induce serum and mucosal immune responses. Biomed Res Int, 2014, 2014, 807539.
66. Santi, L., Batchelor, L., Huang, Z., et al. An efficient plant viral expression system generating orally immunogenic Norwalk virus-like particles. Vaccine 26 (2008), 1846–1854.
67. Zhang, X., Buehner, N.A., Hutson, A.M., et al. Tomato is a highly effective vehicle for expression and oral immunization with Norwalk virus capsid protein. Plant Biotechnol J 4 (2006), 419–432.
68. Xia, M., Farkas, T., Jiang, X., Norovirus capsid protein expressed in yeast forms virus-like particles and stimulates systemic and mucosal immunity in mice following an oral administration of raw yeast extracts. J Med Virol 79 (2007), 74–83.
69. Velasquez, L.S., Hjelm, B.E., Arntzen, C.J., Herbst-kralovetz, M.M., An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles. Clin Vaccine Immunol 17 (2010), 1850–1858.
70. Tacket, C.O., Mason, H.S., Losonsky, G., et al. Human immune responses to a novel Norwalk virus vaccine delivered in transgenic potatoes. J Infect Dis 182 (2000), 302–305.
71. Velasquez, L.S., Shira, S., Berta, A.N., et al. Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine. Vaccine 29 (2011), 5221–5231.